Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN

Pallavi Madhiraju- September 12, 2023 0

Ferring Pharmaceuticals has announced that the first patient in the United States suffering from high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) has been ... Read More

Ferring bags Adstiladrin FDA approval in non-muscle invasive bladder cancer

Raghuram Kadari- December 21, 2022 0

Swiss biopharmaceutical company Ferring Pharmaceuticals has received approval for its Adstiladrin (nadofaragene firadenovec-vncg) gene therapy from the US Food and Drug Administration (FDA) for the treatment ... Read More

Ferring Pharmaceuticals gets Rebyota FDA approval for recurring CDI

Raghuram Kadari- December 2, 2022 0

Rebyota FDA approval : Ferring Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Rebyota (fecal microbiota, live-jslm), a microbiota-based live ... Read More

Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

pharmanewsdaily- November 26, 2019 0

Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in ... Read More

Ferring Pharmaceuticals launches Nocdurna in US to treat nocturia

pharmanewsdaily- November 10, 2018 0

Ferring Pharmaceuticals has announced the launch of Nocdurna (desmopressin acetate) in the United States, marking a significant advancement in the treatment of nocturia caused by ... Read More